These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

885 related articles for article (PubMed ID: 36992275)

  • 21. Pharmaceutical Industry's Engagement in the Global Equitable Distribution of COVID-19 Vaccines: Corporate Social Responsibility of EUL Vaccine Developers.
    Sung M; Huang Y; Duan Y; Liu F; Jin Y; Zheng Z
    Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expanding global vaccine manufacturing capacity: Strategic prioritization in small countries.
    Mukherjee S; Kalra K; Phelan AL
    PLOS Glob Public Health; 2023; 3(6):e0002098. PubMed ID: 37384623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developing-country vaccine manufacturers' technical capabilities can make a difference in global immunization.
    Hayman B; Dennehy M
    Vaccine; 2021 Aug; 39(36):5153-5161. PubMed ID: 34362602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa.
    Bright B; Babalola CP; Sam-Agudu NA; Onyeaghala AA; Olatunji A; Aduh U; Sobande PO; Crowell TA; Tebeje YK; Phillip S; Ndembi N; Folayan MO
    Global Health; 2021 Mar; 17(1):24. PubMed ID: 33658050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increasing efficiency in vaccine Production: A primer for change.
    Aars OK; Clark M; Schwalbe N
    Vaccine X; 2021 Aug; 8():100104. PubMed ID: 34151248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats.
    Hotez PJ; Gilbert S; Saville M; Privor-Dumm L; Abdool-Karim S; Thompson D; Excler JL; Kim JH
    BMJ Glob Health; 2023 Jun; 8(6):. PubMed ID: 37277196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. State capture through indemnification demands? Effects on equity in the global distribution of COVID-19 vaccines.
    Gorodensky A; Kohler JC
    J Pharm Policy Pract; 2022 Aug; 15(1):50. PubMed ID: 35986397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pandemic preparedness and response: beyond the Access to COVID-19 Tools Accelerator.
    Saxena A; Baker BK; Banda A; Herlitz A; Miller J; Karrar K; Fleurbaey M; Chiwa E; Atuire CA; Hirose I; Hassoun N
    BMJ Glob Health; 2023 Jan; 8(1):. PubMed ID: 36650015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic.
    Hotez PJ; Batista C; Amor YB; Ergonul O; Figueroa JP; Gilbert S; Gursel M; Hassanain M; Kang G; Kaslow DC; Kim JH; Lall B; Larson H; Naniche D; Sheahan T; Shoham S; Wilder-Smith A; Sow SO; Strub-Wourgaft N; Yadav P; Bottazzi ME
    EClinicalMedicine; 2021 Sep; 39():101053. PubMed ID: 34368661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries.
    Peacocke EF; Heupink LF; Frønsdal K; Dahl EH; Chola L
    BMJ Open; 2021 Sep; 11(9):e049505. PubMed ID: 34593496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing research and development, launch, and scale up timelines of 18 vaccines: lessons learnt from COVID-19 and implications for other infectious diseases.
    Mao W; Zimmerman A; Urli Hodges E; Ortiz E; Dods G; Taylor A; Udayakumar K
    BMJ Glob Health; 2023 Sep; 8(9):. PubMed ID: 37696544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Access to COVID-19 Vaccines: A New Global Approach.
    Bouderhem R
    Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Collaboration within the global vaccine safety surveillance ecosystem during the COVID-19 pandemic: lessons learnt and key recommendations from the COVAX Vaccine Safety Working Group.
    Chandler RE; Balakrishnan MR; Brasseur D; Bryan P; Espie E; Hartmann K; Jouquelet-Royer C; Milligan J; Nesbitt L; Pal S; Precioso A; Takey P; Chen RT;
    BMJ Glob Health; 2024 Mar; 9(3):. PubMed ID: 38453518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world.
    Perdue ML; Bright RA
    Vaccine; 2011 Jul; 29 Suppl 1():A48-50. PubMed ID: 21684430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring future perspectives and pipeline progression in vaccine research and development.
    Vecchio R; Gentile L; Tafuri S; Costantino C; Odone A
    Ann Ig; 2024; 36(4):446-461. PubMed ID: 38436081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accelerating the development of vaccine microarray patches for epidemic response and equitable immunization coverage requires investment in microarray patch manufacturing facilities.
    Scarnà T; Menozzi-Arnaud M; Friede M; DeMarco K; Plopper G; Hamer M; Chakrabarti A; Gilbert PA; Jarrahian C; Mistilis J; Hesselink R; Gandrup-Marino K; Amorij JP; Giersing B
    Expert Opin Drug Deliv; 2023 Mar; 20(3):315-322. PubMed ID: 36649573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. University contributions to the HPV vaccine and implications for access to vaccines in developing countries: addressing materials and know-how in university technology transfer policy.
    Crager SE; Guillen E; Price M
    Am J Law Med; 2009; 35(2-3):253-79. PubMed ID: 19697749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report.
    Pagliusi S; Hayman B; Jarrett S
    Vaccine; 2021 Apr; 39(18):2479-2488. PubMed ID: 33838948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010.
    ; Ampofo WK; Baylor N; Cobey S; Cox NJ; Daves S; Edwards S; Ferguson N; Grohmann G; Hay A; Katz J; Kullabutr K; Lambert L; Levandowski R; Mishra AC; Monto A; Siqueira M; Tashiro M; Waddell AL; Wairagkar N; Wood J; Zambon M; Zhang W
    Influenza Other Respir Viruses; 2012 Mar; 6(2):142-52, e1-5. PubMed ID: 21819547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.